Monoclonal antibodies (mAbs) are an important therapeutic class with complex
pharmacology and interdependent pharmacokinetic (PK) and pharmacodynamics (PD)
properties. Understanding the PK and PD of mAbs and their biological and mechanistic
underpinnings are crucial in enabling their design and selection, designing appropriate
efficacy and toxicity studies, translating PK/PD parameters to humans, and optimizing dose
and regimen to maximize success in the clinic. Significant progress has been made in this …